[go: up one dir, main page]

GB201120860D0 - Cancer immunotherapy - Google Patents

Cancer immunotherapy

Info

Publication number
GB201120860D0
GB201120860D0 GB201120860A GB201120860A GB201120860D0 GB 201120860 D0 GB201120860 D0 GB 201120860D0 GB 201120860 A GB201120860 A GB 201120860A GB 201120860 A GB201120860 A GB 201120860A GB 201120860 D0 GB201120860 D0 GB 201120860D0
Authority
GB
United Kingdom
Prior art keywords
cancer immunotherapy
immunotherapy
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201120860A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GB201120860A priority Critical patent/GB201120860D0/en
Publication of GB201120860D0 publication Critical patent/GB201120860D0/en
Priority to PCT/EP2012/074570 priority patent/WO2013083659A1/en
Ceased legal-status Critical Current

Links

GB201120860A 2011-12-05 2011-12-05 Cancer immunotherapy Ceased GB201120860D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201120860A GB201120860D0 (en) 2011-12-05 2011-12-05 Cancer immunotherapy
PCT/EP2012/074570 WO2013083659A1 (en) 2011-12-05 2012-12-05 Combination treatment comprising ho - 1 inhibitor and immunotherapeutic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201120860A GB201120860D0 (en) 2011-12-05 2011-12-05 Cancer immunotherapy

Publications (1)

Publication Number Publication Date
GB201120860D0 true GB201120860D0 (en) 2012-01-18

Family

ID=45541205

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201120860A Ceased GB201120860D0 (en) 2011-12-05 2011-12-05 Cancer immunotherapy

Country Status (2)

Country Link
GB (1) GB201120860D0 (en)
WO (1) WO2013083659A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211540T2 (en) * 2014-09-17 2022-05-13 Io Biotech Aps Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
US20170079966A1 (en) * 2014-10-14 2017-03-23 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
WO2017023970A1 (en) * 2015-08-05 2017-02-09 The Board Of Trustees Of The Leland Stanford Junior University Formulations and uses for microparticle delivery of metalloporphyrins
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
GB201601248D0 (en) * 2016-01-22 2016-03-09 Immodulon Therapeutics Ltd Cancer therapy
CN107875168B (en) * 2016-09-30 2022-03-04 广州百吉生物制药有限公司 Application of immunoregulation composition in treating malignant hydrops
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5010073A (en) 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
JP3608788B2 (en) 1992-08-31 2005-01-12 ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ Isolated nonapeptides derived from the MAGE-3 gene and presented by HLA-A1 and their uses
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
DE4311651A1 (en) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
ES2216005T3 (en) 1993-11-09 2004-10-16 Targeted Genetics Corporation PRODUCTION OF ELEVATED TITLES OF RECOMBINANT AAV VECTORS.
FR2716682B1 (en) 1994-01-28 1996-04-26 Centre Nat Rech Scient Process for the preparation of recombinant adeno-associated viruses (AAV) and uses thereof.
FI963393A0 (en) 1994-03-01 1996-08-30 Ludwig Inst Cancer Res Determination of cancer conditions by MAGE gene expression
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (en) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, ESPECIALLY RESTENOSIS
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
GB9606293D0 (en) 1996-03-26 1996-05-29 William Harvey Research Limite Treatment of cancers and other tumours
US6251603B1 (en) 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
WO1999029852A1 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20100158871A1 (en) * 1999-08-30 2010-06-24 David Stephen Terman Sickled erythrocytes with antitumor molecules induce tumoricidal effects
EP1606285A4 (en) 2003-03-27 2009-03-18 Lankenau Inst Medical Res IDO INHIBITORS AND METHODS OF USE THEREOF
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
CA2727528A1 (en) 2007-06-14 2008-12-18 Osta Biotechnologies Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system
WO2010008427A1 (en) 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
HRP20141094T1 (en) 2008-07-08 2015-01-16 Incyte Corporation 1,2,5-OXADIAZOLES AS INDOLAMINE 2,3-DIOXYGENASE INHIBITORS
CA2788284A1 (en) * 2010-02-09 2011-08-18 Georgia Health Sciences University Research Institute, Inc. Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase

Also Published As

Publication number Publication date
WO2013083659A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
EP2758080A4 (en) CANCER IMMUNOTHERAPY
PL3434695T3 (en) Improved immunotherapy
ZA201306944B (en) Individualized vaccines for cancer
HUE059406T2 (en) Pd-l1 based immunotherapy
SG10201610251PA (en) Compositions and methods for cancer immunotherapy
EP2672999A2 (en) Improved immunotherapy
GB201016139D0 (en) Cancer phosholipidome
EP2673635A4 (en) Apoe immunotherapy
GB201120860D0 (en) Cancer immunotherapy
GB201301300D0 (en) No details
GB201114098D0 (en) Armoured over-trousers
ME03498B (en) Individualized vaccines for cancer
GB201119167D0 (en) Novel bachteriophages
GB201106630D0 (en) Cancer therapy
IL229109A0 (en) Diognosis of cancer
GB201107549D0 (en) Cancer vaccine
AU339938S (en) Slide
GB201104514D0 (en) Re-directed immunotherapy
IL228629A0 (en) Cancer detection
GB201110793D0 (en) Easy carry
GB201118220D0 (en) Cancer therapy
GB201109631D0 (en) Better picniks
GB201303586D0 (en) No details
GB201115167D0 (en) No details
GB201216278D0 (en) No details

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)